Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Emavusertib + Pembrolizumab in ICB-Resistant Metastatic Urothelial Cancer
NCT06439836Phase 1Recruiting
- Sponsor
- National Cancer Institute
- Start
- May 2025
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of emavusertib in urothelial carcinoma (UC), sponsored by National Cancer Institute. Primary endpoints: Dose Limiting Toxicities at 3 weeks, Recommended Phase 2 Dose at 3 weeks and 1 more. Started May 2025; status: recruiting.
02
Drugs
emavusertib
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT06439836.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06439836.